Israel Anti-Hypertensive Drugs Market, By Therapeutic Class (Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores), By Region, Competitio
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIsrael Anti-Hypertensive Drugs Market, By Therapeutic Class (Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores), By Region, Competitio
According to World Health Organization 2021, around 1.13 billion people across the world have hypertension, of which two-third are living in low- and middle-income countries.
Hypertension is a preventable risk factor for atherosclerotic diseases and ischemic heart diseases. This condition is marked by high pressure of blood in the arteries. A number of patients maintain suboptimal blood pressure control, despite the modern and effective antihypertensive drugs. Most hypertensive patients require a combination of antihypertensive agents to prevent heart stroke.
Additionally, rise in awareness related to complications associated with hypertension is a major factor that fuels the growth of
Increasing Prevalence of Hypertension
According to United Nations Economic Commission for Europe, Israel has a rapidly aging population, with around 11% of the population aged 65 and over in 2021, and this demographic shift is expected to continue in the coming years.
Additionally, another important factor contributing to the increasing prevalence of hypertension in Israel is unhealthy lifestyle habits, such as a diet high in salt and saturated fat, sedentary behavior, and smoking. These lifestyle factors can increase the risk of hypertension, and are becoming increasingly common in Israel, particularly among younger generations. Obesity, a major risk factor for hypertension, is also on the rise in Israel. According to recent data, the prevalence of obesity among adults in Israel has increased significantly over the past decade, with around 27% of adults now classified as obese. In response to the growing prevalence of hypertension in Israel, healthcare providers are emphasizing the importance of early detection and treatment. Lifestyle changes, such as diet and exercise, can help manage hypertension, but many people also require medications to lower their blood pressure. Ongoing research into new and more effective treatments for hypertension is also essential in combating the growing prevalence of this condition in Israel.
Advancements in Drug Development
For Instance, In December 2021, AbbVie, the parent company of Allergan, lost the patent of its anti-hypertensive drug, Bystolic (Nebivolol).
Additionally, in December 2021, Dr Reddy's Laboratories has launched Valsartan tablets, used for treatment of high blood pressure and heart failure, in the United States market. The Valsartan tablet is the generic therapeutic equivalent of Diovan, approved by the United States Food and Drug Administration (USFDA). Similarly, in November 2021, Otsuka Pharmaceutical Co., Ltd. reported that Novartis Pharma K.K. (Novartis Pharma) has obtained approval in Japan for ENTREST 100 mg and 200 mg Tablets (generic namesacubitril valsartan sodium hydrate) for the new indication of hypertension.
Government Initiatives and Funding
Israel has been collaborating with United Nations to improve the lives of older persons for many years and has worked closely with the United Nations Economic Commission for Europe (UNECE) and its Task Force on Ageing and measuring institutional populations for defining indicators and metrics. Certain other factors that will boost the growth of the Israel anti-hypertensive drugs market include growing initiatives by private and government organizations and rising awareness about hypertension around the around. Few organizations have taken initiatives to conduct a camp and check the blood pressure, making them aware of various aspects of high blood pressure. It certainly adds to the growth of Israel anti-hypertensive market.
The growing awareness of the health risks associated with hypertension in Israel has led to increased efforts to prevent and treat the condition. Public health campaigns, educational programs, and outreach initiatives have been implemented to raise awareness of the importance of managing blood pressure and reducing the risk of hypertension-related health problems. Doctors and other healthcare professionals have increasingly emphasized the importance of monitoring blood pressure and treating hypertension early, to prevent long-term health consequences. As a result, more people are being diagnosed with hypertension and receiving treatment for the condition.
Public health campaigns have also played a role in increasing awareness on the health risks associated with hypertension in Israel. These campaigns aim to educate the public about the importance of healthy lifestyle choices, such as diet and exercise, in preventing hypertension. They also encourage people to get their blood pressure checked regularly and to seek medical treatment if their blood pressure is high. In addition to public health campaigns, educational programs and outreach initiatives have been implemented to raise awareness of hypertension in Israel. These programs focus on educating people about the risk factors for hypertension, the importance of blood pressure monitoring, and the benefits of early intervention and treatment.
The Israel’s Ministry of Health has also taken steps to address the growing prevalence of hypertension by implementing national guidelines for the prevention, diagnosis, and treatment of the condition. These guidelines emphasize the importance of lifestyle modifications, such as reducing salt intake and increasing physical activity, as well as taking medications, when necessary. Therefore, the growing awareness of the health risks associated with hypertension in Israel has led to increased efforts to prevent and treat this condition. The prevalence of hypertension and its associated health risks will continue to decrease in Israel with continued efforts to educate public and these factors propels the growth of Israel anti-hypertensive market.
Download Free Sample Report
Market Segmentation
Israel Anti-Hypertensive Drugs Market can be segmented
Market Players
Pfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Boehringer Ingelheim Israel Ltd., Bristol-Myers Squibb Israel Ltd., Takeda Israel Inc., Teva Israel Ltd., Servier Israel Inc. etc.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2022 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume Units and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends |
| Segments covered | Therapeutic Class Type Distribution Channel Region Company |
| Regional scope | The Mediterranean coastal plain, The Central Hills, The Jordan Rift Valley and The Negev Desert |
| Key companies profiled | Pfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Boehringer Ingelheim Israel Ltd., Bristol-Myers Squibb Israel Ltd., Takeda Israel Inc., Teva Israel Ltd., Servier Israel Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy